We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Apollo Global (APO) Submits Bid to Acquire Concordia
Read MoreHide Full Article
Apollo Global Management, LLC (APO - Free Report) has reportedly submitted a bid in the final round of Concordia Healthcare Corp. auction process. However, there is uncertainty regarding materialization of the deal. The news was reported by The Wall Street Journal on Monday, citing a person acquainted with the matter.
Apollo’s move comes in sharp contrast with the decision of two other private-equity firms – The Blackstone Group L.P. (BX - Free Report) and Carlyle Group LP – that decided not to pursue the acquisition of the Canadian pharmaceutical company despite initially expressing interest in it.
Concerns over Concordia
The report stated that prospective buyers had concerns over Concordia’s ability to sustain its profitability amid the heightened regulatory scrutiny on the health-care sector in the wake of aggressive pricing of drugs by Valeant Pharmaceuticals International, Inc. .
Also the Food and Drug Administration’s efforts to enhance competition in the pharmaceutical industry and restrain the rise in drug prices may affect profitability of Concordia. There are also concerns regarding drug companies in the U.K. as regulators may put a ceiling on the National Health System’s spending on branded drugs and may extend the policy to include generics. Notably, Concordia generates more than half of its revenue from the sale of generics in the U.K., mainly through its Amdipharm Mercury Co. Ltd. acquisition.
On Thursday, Concordia said in a statement that it would continue to review its strategic alternatives. However, at the same time it noted that “there can be no assurance that any transaction will occur”.
What Might have Triggered Apollo’s Interest?
While several private equity firms have shun interest from Concordia, industry participants believe Apollo’s plans might have been driven by the current headwinds faced by Concordia, as the New York-based investment manager has a successful track record of supporting companies that face challenges.
As an investment management firm, Apollo has grown through meaningful acquisitions, strategic alliances and divestures. Apart from health care, the company's interest lies in varied spaces including chemicals, commodities, mining, agriculture, technology, financial services and manufacturing. We look forward to the company's greater involvement in deals that augur well for its growth.
However, we remain concerned about the adverse effects of the present capital market volatility and stringent regulatory landscape that could weigh on the company's financial performance in the near term.
Apollo Global currently carries a Zacks Rank #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Apollo Global (APO) Submits Bid to Acquire Concordia
Apollo Global Management, LLC (APO - Free Report) has reportedly submitted a bid in the final round of Concordia Healthcare Corp. auction process. However, there is uncertainty regarding materialization of the deal. The news was reported by The Wall Street Journal on Monday, citing a person acquainted with the matter.
Apollo’s move comes in sharp contrast with the decision of two other private-equity firms – The Blackstone Group L.P. (BX - Free Report) and Carlyle Group LP – that decided not to pursue the acquisition of the Canadian pharmaceutical company despite initially expressing interest in it.
Concerns over Concordia
The report stated that prospective buyers had concerns over Concordia’s ability to sustain its profitability amid the heightened regulatory scrutiny on the health-care sector in the wake of aggressive pricing of drugs by Valeant Pharmaceuticals International, Inc. .
Also the Food and Drug Administration’s efforts to enhance competition in the pharmaceutical industry and restrain the rise in drug prices may affect profitability of Concordia. There are also concerns regarding drug companies in the U.K. as regulators may put a ceiling on the National Health System’s spending on branded drugs and may extend the policy to include generics. Notably, Concordia generates more than half of its revenue from the sale of generics in the U.K., mainly through its Amdipharm Mercury Co. Ltd. acquisition.
On Thursday, Concordia said in a statement that it would continue to review its strategic alternatives. However, at the same time it noted that “there can be no assurance that any transaction will occur”.
What Might have Triggered Apollo’s Interest?
While several private equity firms have shun interest from Concordia, industry participants believe Apollo’s plans might have been driven by the current headwinds faced by Concordia, as the New York-based investment manager has a successful track record of supporting companies that face challenges.
As an investment management firm, Apollo has grown through meaningful acquisitions, strategic alliances and divestures. Apart from health care, the company's interest lies in varied spaces including chemicals, commodities, mining, agriculture, technology, financial services and manufacturing. We look forward to the company's greater involvement in deals that augur well for its growth.
However, we remain concerned about the adverse effects of the present capital market volatility and stringent regulatory landscape that could weigh on the company's financial performance in the near term.
Apollo Global currently carries a Zacks Rank #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>